Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658528 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00658528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00658528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2008
Completion date
January 31, 2010
Enrollment
1,061 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux disease (gerd)